Smart Phone Reader Detects Common Pathogens
|
By LabMedica International staff writers Posted on 10 May 2018 |

Image: The low-cost, portable laboratory on a phone that can interpret results from a microplate assay (Photo courtesy of Washington State University).
In rural or low resource areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.
A low-cost, portable laboratory on a phone has been developed that works nearly as well as clinical laboratories to detect common viral and bacterial infections. The work could lead to faster and lower-cost laboratory results for fast-moving viral and bacterial epidemics.
Bioengineers at Washington State University (Pullman, WA, USA) and their colleagues developed an ultra-low-cost clinically accurate mobile phone microplate reader (mReader), and clinically validated this optical device for 12 infectious disease tests. The mReader optically reads 96 samples on a microplate at one time. The team tested 771 de-identified patient samples for 12 serology assays for bacterial/viral infections. The mReader and the clinical instrument blindly read and analyzed all tests in parallel.
The scientists evaluated the analytical accuracy and the diagnostic performance of the mReader across the clinical reportable categories by comparison with clinical laboratorial testing results. The mReader exhibited 97.6% to 99.9% analytical accuracy and <5% coefficient of variation (CV). The positive percent agreement (PPA) in all 12 tests achieved 100%, negative percent agreement (NPA) was higher than 83% except for one test (42.9%), and overall percent agreement (OPA) ranged 89.3% to100%. The team was able to build the device for about USD 50, but the manufacturing cost would probably be lower than that.
The authors envision the mReader can benefit underserved areas/populations and low-resource settings in rural clinics/hospitals at a low cost with clinical-level analytical quality. It has the potential to improve health access, speed up healthcare delivery, and reduce health disparities and education disparities by providing access to a low-cost spectrophotometer. The study was published on March 23, 2018, in the journal Clinica Chimica Acta.
Related Links:
Washington State University
A low-cost, portable laboratory on a phone has been developed that works nearly as well as clinical laboratories to detect common viral and bacterial infections. The work could lead to faster and lower-cost laboratory results for fast-moving viral and bacterial epidemics.
Bioengineers at Washington State University (Pullman, WA, USA) and their colleagues developed an ultra-low-cost clinically accurate mobile phone microplate reader (mReader), and clinically validated this optical device for 12 infectious disease tests. The mReader optically reads 96 samples on a microplate at one time. The team tested 771 de-identified patient samples for 12 serology assays for bacterial/viral infections. The mReader and the clinical instrument blindly read and analyzed all tests in parallel.
The scientists evaluated the analytical accuracy and the diagnostic performance of the mReader across the clinical reportable categories by comparison with clinical laboratorial testing results. The mReader exhibited 97.6% to 99.9% analytical accuracy and <5% coefficient of variation (CV). The positive percent agreement (PPA) in all 12 tests achieved 100%, negative percent agreement (NPA) was higher than 83% except for one test (42.9%), and overall percent agreement (OPA) ranged 89.3% to100%. The team was able to build the device for about USD 50, but the manufacturing cost would probably be lower than that.
The authors envision the mReader can benefit underserved areas/populations and low-resource settings in rural clinics/hospitals at a low cost with clinical-level analytical quality. It has the potential to improve health access, speed up healthcare delivery, and reduce health disparities and education disparities by providing access to a low-cost spectrophotometer. The study was published on March 23, 2018, in the journal Clinica Chimica Acta.
Related Links:
Washington State University
Latest Microbiology News
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
- Genetic Studies Uncover Mechanisms Driving Drug Resistance in Superbugs
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
- Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
- Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
- New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
- Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Channels
Clinical Chemistry
view channel
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read moreMolecular Diagnostics
view channel
Rapid Genetic Test Aims to Shorten Brain Tumor Diagnosis Time
Brain tumors can be highly aggressive and difficult to treat, and The Brain Tumour Charity describes them as the biggest cancer killer of children and adults under 40. With more than 100 recognized tumor... Read more
New Oncology Assays Deliver Precise Molecular Counts with MRD-Grade Sensitivity
Precise molecular monitoring is central to managing hematologic malignancies, but traditional PCR workflows can limit sensitivity, multiplexing, and result clarity. Limited sample volumes and fragmented... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read moreMicrobiology
view channel
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







